Skip to content
Screener

Inhibrx Biosciences, Inc. INBX EPS (Diluted)

EPS (Diluted) at other companies

Pfizer logo
PfizerPFE
-$0.04-108%
Rogers Corporation logo
Rogers CorporationROG
$0.76+119%
Merck & Co. logo
Merck & Co.MRK
-$0.54-131%
Gilead Sciences logo
Gilead SciencesGILD
-$8.45-642%
Nuvation Bio logo
Nuvation BioNUVB
-$0.18-5.9%
Immunome logo
ImmunomeIMNM
-$0.65-30.0%

Other financials

Income statement

See full
Revenue--100%
Operating income-$32.1M-17.4%
Net income-$36.7M-27.9%

Balance sheet

See full
Cash & equivalents$133.3M-28.5%
Total debt$181.6M+70.1%
Total equity-$53.0M-177%
Total assets$154.2M-27.3%

Cash flow

See full
Operating cash flow-$29.9M+0.1%
CapEx-—
Free cash flow-$29.9M+0.1%

Valuation

See full
Market cap$1.44B+184%
Enterprise value$1.49B+223%
P/S1,108.7×-290×

Profitability

See full
Operating margin-10,386.5%-5,025pp
Net margin-10,773.5%-878,492pp
FCF margin-9,986.5%-4,727pp

Returns & leverage

See full
Return on equity-197.8%-2,158pp
Debt / equity13.4×+13.3×
Current ratio5.1×+0.1×

Where this comes from

Reported directly by Inhibrx Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: Inhibrx Biosciences, Inc.’s 10-Q, filed August 13, 2026.

Filed
Aug 13, 2026, 4:04 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0002007919-26-000042
Line itemTHREE MONTHS ENDEDJUNE 30, 2026THREE MONTHS ENDEDJUNE 30, 2025SIX MONTHS ENDEDJUNE 30, 2026SIX MONTHS ENDEDJUNE 30, 2025
Interest income1,2632,1242,2704,453
Other expense, net(68)(246)(80)(296)
Total other expense(4,498)(1,263)(7,012)(1,673)
Loss before income tax expense(36,647)(28,652)(70,088)(71,963)
Provision for income taxes3232
Net loss$(36,650)$(28,654)$(70,091)$(71,965)
Net loss per share, basic and diluted$(2.34)$(1.85)$(4.49)$(4.65)
Shares used in computing net loss per share, basic and diluted15,66915,46815,62715,468

Item 1. Financial Statements (unaudited)

FAQ

What is Inhibrx Biosciences, Inc.'s EPS (diluted)?
Inhibrx Biosciences, Inc. (INBX) reported EPS (diluted) of -$2.34 in Q2 2026.
How has Inhibrx Biosciences, Inc.'s EPS (diluted) changed year-over-year?
Inhibrx Biosciences, Inc.'s EPS (diluted) decreased by 26.5% year-over-year, from -$1.85 to -$2.34.
What is the long-term trend for Inhibrx Biosciences, Inc.'s EPS (diluted)?
Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s EPS (diluted) has grown at a -33.6% compound annual growth rate (CAGR), from -$20.48 to -$9.04.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about Inhibrx Biosciences, Inc.'s eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude